Vincristine
- Generic Name
- Vincristine
- Brand Names
- Marqibo, Vincasar
- Drug Type
- Small Molecule
- Chemical Formula
- C46H56N4O10
- CAS Number
- 57-22-7
- Unique Ingredient Identifier
- 5J49Q6B70F
- Background
Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).
- Indication
Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
- Associated Therapies
- -
Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2018-07-16
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 18
- Registration Number
- NCT03586999
- Locations
- 🇺🇸
City of Hope Cancer Center, Duarte, California, United States
🇺🇸University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: RuxolitinibDrug: CyclophosphamideDrug: CytarabineDrug: MercaptopurineDrug: VincristineDrug: PegaspargaseDrug: RituximabDrug: Methotrexate (Intrathecal Administration)Drug: Methotrexate (Intravenous Administration)Drug: DexamethasoneDrug: DoxorubicinDrug: ThioguanineDrug: Methotrexate Oral Product
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 15
- Registration Number
- NCT03571321
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL
- Conditions
- Interventions
- Drug: DexamethasoneDrug: vincristineDrug: CyclophosphamideDrug: IdarubicinDrug: PegaspargaseDrug: AdriamycinDrug: MethotrexateDrug: 6-mercaptopurine.Drug: EtoposideDrug: CytarabineProcedure: Bone marrow aspirationProcedure: Intrathecal injectionRadiation: Radiation therapyGenetic: NGSProcedure: allogeneic hematopoietic stem cell transplantationDiagnostic Test: Flow-MRDDiagnostic Test: FISHDiagnostic Test: Flow immunophenotypingDiagnostic Test: KaryotypingDrug: ChidamideDiagnostic Test: PET-CT scan
- First Posted Date
- 2018-06-21
- Last Posted Date
- 2018-06-21
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 80
- Registration Number
- NCT03564704
- Locations
- 🇨🇳
Department of Hematology, Nanfang Hospital, Guangzhou, Guangdong, China
Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- Southwest Hospital, China
- Target Recruit Count
- 100
- Registration Number
- NCT03553537
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL
- Conditions
- Interventions
- Drug: ChidamideDrug: DexamethasoneDrug: vincristineDrug: CyclophosphamideDrug: IdarubicinDrug: PegaspargaseDrug: AdriamycinDrug: MethotrexateDrug: 6-MercaptopurineDrug: EtoposideDrug: CytarabineProcedure: Bone marrow aspirationProcedure: Intrathecal injectionRadiation: Radiation therapyGenetic: NGSProcedure: allogeneic hematopoietic stem cell transplantationDiagnostic Test: Flow-MRDDiagnostic Test: FISHDiagnostic Test: Flow immunophenotypingDiagnostic Test: Karyotyping
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 70
- Registration Number
- NCT03553238
- Locations
- 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor
- Conditions
- Interventions
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Andres J. M. Ferreri
- Target Recruit Count
- 28
- Registration Number
- NCT03536039
- Locations
- 🇮🇹
Ospedale San Raffaele, Milan, Italy
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL
- Conditions
- Interventions
- First Posted Date
- 2018-03-16
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 172
- Registration Number
- NCT03467373
- Locations
- 🇩🇰
Rigshospitalet; Hæmatologisk Klinik, Klinisk Afprøvnings Team KAT, København Ø, Denmark
🇺🇸University of Alabama Medical Center, Birmingham, Alabama, United States
🇺🇸Fox Chase-Temple Cancer Center, Philadelphia, Pennsylvania, United States
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 340
- Registration Number
- NCT03407144
- Locations
- 🇺🇸
University of Chicago ( Site 0066), Chicago, Illinois, United States
🇺🇸Cohen Children's Medical Center of New York ( Site 0052), New Hyde Park, New York, United States
🇺🇸Columbia University/Herbert Irving Cancer Center ( Site 0063), New York, New York, United States
A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- First Posted Date
- 2017-12-27
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 47
- Registration Number
- NCT03384654
- Locations
- 🇺🇸
Children'S Healthcare Of Atlanta/Emory Univ. Dept. Of Pediatrics, Atlanta, Georgia, United States
🇺🇸Newark Beth Israel Medical Center, Newark, New Jersey, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
Irinotecan and Temozolomide for Ewing Sarcoma
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2022-11-01
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT03359005
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.